… muscarinic antagonist glycopyrronium (NVA237) for the treatment of chronic obstructive
pulmonary disease (COPD). We investigated the safety and efficacy of QVA149 over 52 weeks. …

… The aim of this review is to present the clinical data on the efficacy and safety of cilomilast
in patients with chronic obstructive pulmonary disease (COPD). Over 6000 COPD patients …

… Our meta-analysis suggests that COPD patients treated with inhaled corticosteroids experience
significantly fewer exacerbations than patients on placebo. The relative risk reduction is …

… synthesis to compare the efficacy and safety profile of different xanthines in COPD. … data
on safety as a function of person-weeks. Data obtained from 998 COPD patients were selected …

… In COPD patieNts; ATTAIN), which assessed the efficacy and safety of aclidinium 200 μg
and 400 μg bid versus placebo over 24 weeks in patients with moderate to severe COPD. …

… the efficacy and safety of 12-week twice-daily aclidinium 200 μg and 400 μg in COPD patients.
… , suggesting that the higher aclidinium dose provides greater efficacy in COPD patients …

… The safety profile of tiotropium in a primary care COPD population was … the efficacy and
safety of tiotropium 18 μg via the HandiHaler ® in a representative primary care-managed COPD …

… a safe and effective bronchodilator, is the only licensed LAMA available currently for
COPD patients and … the efficacy and safety of NVA237 50 μg qd in patients with moderate-to-severe …

… of hypoxaemic COPD patients with … as safety of HFOT as assessed by lung volume changes.
Thus, our study verifies for the first time that HFOT is safe and efficacious in COPD patients …

… The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the
efficacy, safety and tolerability of NVA237 in patients with moderate-to-severe COPD. …